-
Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation
At the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference, the research team led by Dr. Xiaoyu Zhu and Dr. Aijie Huang from The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) garnered significant attention. Their study on the efficacy and safety of avatrombopag for treating…
-
Dr. Baohui Han Analyzes the Relationship Between PD-L1 Expression and Crizotinib Efficacy in ROS-1 Fusion-Positive NSCLC
The development of modern oncology has provided a variety of groundbreaking treatment options for lung cancer, making it one of the most rapidly evolving solid tumors. To help clinical physicians gain an in-depth and comprehensive understanding of the significant advancements in this field, “Oncology Frontier” has joined forces with Dr. Hua Zhong and Dr. Baohui…
-
Eur Urol | Biomarkers in Prostate Cancer Screening: Sometimes, “More Is Better”
Prostate cancer is one of the most common malignancies in men, and the widespread use of prostate-specific antigen (PSA) testing has significantly improved early diagnosis rates. However, a series of prostate cancer screening trials in Europe have found that PSA-based screening benefits only a subset of patients. How can more prostate cancer patients benefit from…
-
WCLC 2024 | Global Survey: Barriers to Optimal Biomarker Testing for Lung Cancer
The 2024 World Conference on Lung Cancer (WCLC) will be held in San Diego, USA, from September 7-10. Dr. Matthew Smeltzer, Associate Professor , Division of Epidemiology, Biostatistics, and Environmental Health at the University of Memphis, Tennessee, will present the analysis of the “2024 International Association for the Study of Lung Cancer (IASLC) Global Survey…
-
Annual Review | Academician Xu Zhang: Chinese Doctors Leading a New Revolution in Urological Surgery Innovation
Time rewards those who strive, and success comes to those who persevere. As 2023 draws to a close, the year has left behind many noteworthy achievements in China’s field of urology, especially in the areas of prostate cancer surgery and drug treatments. On this occasion, Urology Frontier interviewed Xu Zhang, Academician of the Chinese PLA…
-
Academician Xu Zhang: “Nivolumab” Assists in UC Treatment, Filling the Gap in First-Line mUC Therapy, Leading the Era of Immunotherapy for UC
At the 2023 ESMO Congress, the field of urothelial carcinoma (UC) witnessed a major breakthrough. The global multicenter Phase III CheckMate-901 study showed that in the first-line treatment of unresectable or metastatic urothelial carcinoma (mUC), nivolumab combined with cisplatin-based chemotherapy achieved dual positive results in the co-primary endpoints of overall survival (OS) and progression-free survival…
-
Academician Xu Zhang’s Team Showcases the Expertise of Chinese Urology at the SRS World Robotic Surgery Society
In the winter along the Neckar River, Heidelberg’s old town was adorned in snow, providing a fitting backdrop for an academic atmosphere rich in culture and freedom. The “Semi-Live 2024” International Urology Conference and the CGAU Academic Annual Meeting between China and Germany were successfully held from January 18 to 20 in Heidelberg, a hub…
-
Delicate and Thin Fibrous Septa Indicate a Regression Tendency in MASH Patients with Advanced Fibrosis
Previous studies have demonstrated that liver fibrosis can be reversible if the underlying cause is controlled. Wanless and colleagues described the pathological changes associated with cirrhosis regression in chronic hepatitis…
Connecting Medical Expertise through Media